Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.54 -0.14 (-0.20%)
Streaming Delayed Price Updated: 9:59 AM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab
Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER). 
Via Talk Markets
US Stocks On Recovery Course As Earnings Lend Support: Fed's Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst
The see-sawing mood in the market continues as Fed’s data dependency creates volatility. The index futures point to a solidly higher opening on Thursday, signaling a reversal in the sentiment seen in... 
Via Benzinga
AstraZeneca Earnings Preview
Via Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years. 
Via The Motley Fool
AZN Stock Under Pressure
Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses. 
Via Talk Markets
The Top Healthcare Stocks to Buy With $100
Don't overlook these big-name foreign healthcare stocks. 
Via The Motley Fool
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
Via Investor Brand Network
Exposures COVID-19 Product Safety
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
Danaher Corporation (NYSE: DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE: CTLT). 
Via Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Via Benzinga
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
From AstraZeneca
Via Business Wire
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
These healthcare titans are poised for a strong showing in 2023 and beyond. 
Via The Motley Fool
These 2 Healthcare Stocks Have Doubled in 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks. 
Via MarketBeat
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths. 
Via Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Exposures Product Safety
Could This Vaccine Become Sanofi's Latest Blockbuster?
This vaccine candidate could be approved in newborns and infants later this year. 
Via The Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug. 
Via The Motley Fool
7 Dividend Stocks to Buy for a Stable Income Stream
These are the dividend stocks to buy for a regular income stream and potential capital gains as these stocks trade at attractive valuations. 
Via InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook. 
Via The Motley Fool
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
From AstraZeneca
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
After years of lab failures, the companies could crack open a multibillion-dollar market. 
Via Investor's Business Daily
AstraZeneca’s Next “Wonder Drug”
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key... 
Via Talk Markets
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.